Navigation Links
DrugRisk News: Court Consolidates Januvia Lawsuits Alleging Cancer
Date:9/4/2013

New York, NY (PRWEB) September 04, 2013

The diabetes drug safety center at DrugRisk.com is announcing new information on the site for patients taking the medications Januvia or Janumet. A federal panel recently ordered the consolidation of a growing number of lawsuits alleging the drugs caused pancreatic cancer*.

DrugRisk is a resource center designed to give patients taking popular prescription drugs like Januvia the latest warnings, recalls, studies and legal news. Visitors can see if others are experiencing similar side effects and decide if they need legal advice.

Januvia and Janumet are diabetes medications prescribed to those with type-2 diabetes, taken twice a day to lower blood sugar levels. In recent years, they have been the best-selling drugs for Merck, bringing in over $4 billion last year**.

However, DrugRisk has added studies that link Januvia and Janumet to cancer. A 2011 study from UCLA linked Januvia with increased rates of pancreatic cancer and thyroid cancer***. The American Medical Association recently advised diabetes drugs like these can double the risk of pancreatitis, a major risk factor for pancreatic cancer****.

Now, with a growing number of patients filing a Januvia lawsuit alleging cancer, the Judicial Panel on Multidistrict Litigation ordered last week that cases will be consolidated to a special multidistrict litigation federal court. (In Re: Incretin-Based Therapies Products Liability Litigation, MDL 2452, Southern District of California)*.

Anyone affected by cancer after taking Januvia or Janumet is encouraged to speak with a lawyer about their legal options. However, due to the specialized nature of federal drug injury cases, DrugRisk only recommends lawyers who have already handled Januvia lawsuits.

For more information on the research, side effects and litigation news related to Januvia and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.

*JPML 8/26/13; jpml.uscourts.gov/sites/jpml/files/MDL-2452-Initial_Transfer-07-13.pdf
**Bloomberg, 2/25/13; bloomberg.com/news/2013-02-25/merck-bristol-diabetes-drugs-linked-to-pancreatitis-risk.html
***Gastroenterology, July 2011; ctsi.ucla.edu/education/files/publicview/training/docs/FDA-analysis.pdf
****JAMA Internal Medicine, 2/25/13; archinte.jamanetwork.com/article.aspx?articleid=1656537

Read the full story at http://www.prweb.com/releases/2013-januvia-side-effects/lawsuit-litigation/prweb11085046.htm.


'/>"/>
Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related medicine news :

1. DrugRisk Update: Court Issues Latest Decision in Pradaxa Bleeding Litigation
2. DrugRisk Update: New Study Warns of Pradaxa Dangers as Lawsuits Increase
3. DrugRisk Update: Panel To Decide Fate of Januvia Lawsuits Next Week
4. DrugRisk Announces Latest Ruling By Judicial Panel on NuvaRing Lawsuits
5. DrugRisk Announces Drop in Yaz Lawsuits As Bayer Commits $1.5 Billion to Settlements
6. DrugRisks Announces Yaz Center With Latest Updates on Blood Clot Warnings and Settlements
7. DrugRisks Update: New Study Warns of Pradaxa Brain Bleeding
8. DrugRisk Update Shows Increase in NuvaRing Blood Clot Lawsuits
9. Latest Court Records Show 6% Increase In NuvaRing Lawsuits, DrugRisks Notes
10. DrugRisk News: Federal Panel Issues Latest Mirena Lawsuit Updates
11. DrugRisks Update: Latest Court Figures Show Rise In Pradaxa Lawsuits
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/9/2016)... ... February 09, 2016 , ... A new study from ... and Medicare rates for a variety of medical services in Illinois as of ... the 2015 Fee Schedule Rates in Illinois, are professional medical services, hospital ...
(Date:2/9/2016)... (PRWEB) , ... February 09, ... ... print and e-book publishing software, in partnership with Snowfall4pod Digital, creators of ... a comprehensive book publishing, content management, global distribution and print-on-demand network. , ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Establishment Labs, ... of Dr. David Hung to the company´s Board of Directors. , “We ... class scientist and an exceptional entrepreneur.” said Juan Jose Chacon Quiros, CEO of Establishment ...
(Date:2/9/2016)... ... February 10, 2016 , ... The Journal of Pain Research has ... field .” , As corresponding author Dr John F. Peppin says “Terminology matters, yet ... our chronic pain patients. ‘Chronic cancer pain’ and ‘chronic non-cancer pain’ are replete ...
(Date:2/9/2016)... (PRWEB) , ... February 09, 2016 , ... Dr. Rassouli, ... whitening packages. Teeth whitening is among the most popular cosmetic procedures in dentistry today, ... whitening needs. This can put them at risk of teeth whitening-related damage. For a ...
Breaking Medicine News(10 mins):
(Date:2/9/2016)...  Sangamo BioSciences, Inc. (NASDAQ: SGMO ), ... its fourth quarter and full year 2015 financial ... therapeutic genome editing," said Edward Lanphier, Sangamo,s president ... (ZFN) technology leads the therapeutic genome editing field ... to move our ground-breaking genome editing programs through ...
(Date:2/9/2016)... Mast Therapeutics, Inc. (NYSE MKT: MSTX), ... disease and heart failure, today announced that it intends to ... stock in an underwritten public offering.  The offering is subject ... assurance as to whether or when the offering may be ... the offering.   --> --> ...
(Date:2/9/2016)... The global prefilled syringes market accounted for $3,905.1 million ... with a CAGR of 12.9% during 2015-2020. Among the ... global prefilled syringes market, with 90.1% share in 2014. ... global market of prefilled syringes is up surging with ... demand for vaccines, increasing prevalence of chronic and lifestyle ...
Breaking Medicine Technology: